Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer

Clinical Breast Cancer

Volumn 15, Issue 1, 2015, Pages 24-30

  Mayer, Erica L ^a   Gropper, Adrienne B ^b   Harris, Lyndsay ^c   Gold, Julie M ^d   Parker, Leroy ^a   Kuter, Irene ^e   Come, Steven ^f   Najita, Julie S ^a   Guo, Hao ^a   Winer, Eric P ^a   Burstein, Harold J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d Mt Kisco Medical Group   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Anthracycline; Cardiotoxicity; Neoadjuvant therapy; Pathologic complete response

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CARDIOTOXICITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PREOPERATIVE PERIOD; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; MASTECTOMY; MIDDLE AGED; UPREGULATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; PREOPERATIVE PERIOD; RECEPTOR, ERBB-2; TREATMENT OUTCOME; UP-REGULATION;

EID: 84920278742     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.07.010     Document Type: Article

References (32)

1. S. Paik, R. Hazan, and E.R. Fisher Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer J Clin Oncol 8 1990 103 112
2. E.H. Romond, E.A. Perez, and J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
3. M.J. Piccart-Gebhart, M. Procter, and B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
4. D. Slamon, W. Eiermann, and N. Robert Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 2011 1273 1283
5. B.P. Coudert, R. Largillier, and L. Arnould Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial J Clin Oncol 25 2007 2678 2684
6. H.J. Burstein, L.N. Harris, and R. Gelman Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study J Clin Oncol 21 2003 46 53
7. A.U. Buzdar, N.K. Ibrahim, and D. Francis Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 2005 3676 3685
8. L. Gianni, W. Eiermann, and V. Semiglazov Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375 2010 377 384
9. M. Untch, P.A. Fasching, and G.E. Konecny Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups J Clin Oncol 29 2011 3351 3357
10. J. Baselga, I. Bradbury, and H. Eidtmann Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet 379 2012 633 640
11. L. Gianni, T. Pienkowski, and Y.H. Im Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 2012 25 32
12. G. von Minckwitz, M. Untch, and J.U. Blohmer Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol 30 2012 1796 1804
13. L.N. Harris, F. You, and S.J. Schnitt Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer Clin Cancer Res 13 2007 1198 1207
14. E.A. Mittendorf, Y. Wu, and M. Scaltriti Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes Clin Cancer Res 15 2009 7381 7388
15. A.U. Buzdar, V. Valero, and N.K. Ibrahim Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen Clin Cancer Res 13 2007 228 233
16. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
17. M. Greenwood Reports on public health and medical subjects: the errors of sampling of the survivorship tables 1926 HM Stationery Office London
18. M. Kaufmann, G. von Minckwitz, and E.P. Mamounas Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer Ann Surg Oncol 19 2012 1508 1516
19. H.D. Bear, S. Anderson, and R.E. Smith Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 24 2006 2019 2027
20. T.M. Prowell, and R. Pazdur Pathological complete response and accelerated drug approval in early breast cancer N Engl J Med 366 2012 2438 2441
21. M. Untch, M. Rezai, and S. Loibl Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study J Clin Oncol 28 2010 2024 2031
22. J. Hurley, P. Doliny, and I. Reis Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer J Clin Oncol 24 2006 1831 1838
23. D. Pectasides, A. Gaglia, and P. Arapantoni-Dadioti HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy Anticancer Res 26 2006 647 653
24. E. Amir, N. Miller, and W. Geddie Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer J Clin Oncol 30 2012 587 592
25. S.D. Russell, K.L. Blackwell, and J. Lawrence Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials J Clin Oncol 28 2010 3416 3421
26. M. Procter, T.M. Suter, and E. de Azambuja Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial J Clin Oncol 28 2010 3422 3428
27. M.L. Telli, S.A. Hunt, and R.W. Carlson Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility J Clin Oncol 25 2007 3525 3533
28. E.H. Romond, J.H. Jeong, and P. Rastogi Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 30 2012 3792 3799
29. E. Tan-Chiu, G. Yothers, and E. Romond Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 J Clin Oncol 23 2005 7811 7819
30. E.A. Perez, V.J. Suman, and N.E. Davidson Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial J Clin Oncol 26 2008 1231 1238
31. N. Harbeck, M.S. Ewer, and M. De Laurentiis Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy Ann Oncol 22 2011 1250 1258
32. H. Joensuu, P.L. Kellokumpu-Lehtinen, and P. Bono Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 2006 809 820